ClinicalTrials.gg
Active, not recruitingNCT02344472Updated Jun 4, 2024

Detect V / CHEVENDO (Chemo vs. Endo)

A Phase 3 interventional study of pertuzumab and Trastuzumab in Metastatic Breast Cancer, sponsored by Prof. Wolfgang Janni. Active, not recruiting at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-04.

Sponsored by Prof. Wolfgang Janni · Phase 3, Interventional, and Treatment

How we know · 36 judgments

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
271
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies testing exemestane in Breast Neoplasms — 20 open to participants now, 26 under way, 7 of them phase 3. exemestane · Breast Neoplasms.

Enrollment
35th of 101
271 · median 123
Started
2015
with 2 others
Phase 3
34 of 103
5 open now
Primary completion
2025-01
later than 4 of 25 live
Registered
59th of 103
by date

Among the 103 studies testing exemestane in Breast Neoplasms, this one is the 35th largest by enrollment of the 101 interventional ones that give a count, is one of 3 that started in 2015, is one of 34 in phase 3, reaches primary completion later than 4 of the 25 other live ones, and was the 59th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 103 studies testing exemestane in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About exemestane

exemestane: first FDA approval 1999 (AROMASIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies testing exemestane in Breast Neoplasms, or all of them as a file.
02

Study summary

Chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.

Read the detailed description

Especially for diseases that are not curable such as metastatic breast cancer (MBC), the maintenance of quality of life is one of the main aims of treatments. Adverse events are well-known side effects of any cytostatic treatment and impact the patients' quality of life. Therefore, new treatment options are developed that should stop or at least slow down metastatic spread of cancer without causing negative side effects in terms of high-grade adverse events. For patients with hormone-receptor positive and HER2 positive MBC the combination of HER2-targeted therapy with endocrine therapy has already been proven to be an effective and in many cases valuable alternative to the combination of HER2-targeted therapy with chemotherapy. The high relevance of HER2-neu-targeted/endocrine treatment combinations derives from the fact that potential chemotherapy-related toxicity can be avoided, which in turn positively affects quality of life. Clinical trials suggest an additional benefit when a CDK4/6 inhibitor is added to the combination of endocrine therapy and anti HER2 treatment. DETECT V is a randomized phase III study comparing the safety and efficacy of trastuzumab plus pertuzumab and the CDK 4/6 inhibitor ribociclib in combination with either endocrine therapy or chemotherapy.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • MBC
  • HER2
  • CTC
  • endocrine therapy
  • Pertuzumab
  • Trastuzumab
  • HER2 therapy
  • Ribociclib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed, written in study participation
  • The primary tumor and/or from sites or locoregional recurrences have been confirmed as -positive (FISH-positive or IHC 3+) and hormone receptor positive breast cancer by histopathology according to local testing
  • Metastatic breast cancer or locally advanced BC, which cannot be treated by surgery or radiotherapy only
  • Pre- and women are allowed
  • No more than two prior chemotherapies for metastatic disease
  • No more than two prior anti-HER2 therapies for metastatic disease
  • Pertuzumab retreatment is allowed if prior pertuzumab treatment was finished 12 months before
  • At least one assessable using standard techniques by Version 1.1 (RECIST v1.1)
  • Tumor evaluation according to RECIST version 1.1 has been performed within 4 weeks before randomization based on local assessment
  • Age ≥ 18 years
  • Standard 12-lead values assessed by the local laboratory:

    • interval at screening \< 450 msec (using Fridericia's correction)
    • Resting heart rate 50-90 bpm
  • Left ventricular cardiac (LVEF) ≥ 50% at baseline (as measured by echocardiogram)
  • Score ≤ 2
  • Adequate organ function within 14 days before randomization, evidenced by the following laboratory results below:

    • ≥ 1500 cells/µL,
    • count ≥ 100000 cells/µL,
    • ≥ 9 g/dL,
    • (SGPT) ≤ 2.0 × (≤ 3.0 × ULN in case of liver metastases)
    • AST (SGOT) ≤ 2.0 × ULN (≤ 3.0 × ULN in case of liver metastases)
    • ≤ 1.5 × ULN (with the exception of Gilbert's syndrome)
    • creatinine ≤ 2.0 mg/dl or 177µmol/L ≤ 1,5
  • Patients must have the following laboratory values within normal limits or corrected to within normal limits with supplemets before the first dose of study medication:

    • Sodium
    • Potassium
    • Total calcium
  • In case of patients of child bearing potential:

Negative serum pregnancy test at baseline (within 7 days prior to randomization) and agreement to remain abstinent (if it is in line with the preferred and usual lifestyle) or use single or combined non-hormonal methods that result in a failure rate of \< 1% per year during the treatment period and for at least 7 months after the last dose of study treatment

Exclusion criteria

Exclusion criteria:

Patients will be excluded from the study for any of the following reasons:

  • History of reactions attributed to trastuzumab, pertuzumab, ribociclib or to other components of drug formulation
  • Mandatory need for cytostatic treatment at time of study entry based on clinical judgment and national/international treatment guidelines
  • Known
  • Any concurrent severe, uncontrolled systemic disease, social or psychiatric condition that might interfere with the planned treatment and with the patient's adherence to the protocol
  • Progression on prior Pertuzumab therapy
  • Treatment with Pertuzumab within the last 12 months
  • Prior treatment with any mTOR- or CDK4/6-inhibitor
  • Treatment with any other agents during trial
  • Known hypersensitivity to lecithin (soya) or peanuts
  • \< 6 months
  • Patients with pre-existing grade ≥2 peripheral neuropathy are excluded from taxane-based chemotherapy
  • History of serious cardiac disease, including but not confined to:

    • history of documented heart failure or systolic dysfunction ( \< 50%)
    • high-risk uncontrolled arrhythmias i.e., atrial tachycardia with a heart rate ≥100/min at rest, significant ventricular arrhythmia (ventricular tachycardia) or higher-grade AV-block (second degree AV-block Type 2 [Mobitz 2] or third degree AV-block)
    • angina pectoris requiring anti-anginal medication
    • valvular heart disease
    • evidence of transmural infarction on
    • poorly controlled hypertension (e.g., systolic >180 mm Hg or diastolic >100 mm Hg)
    • any other cardiac condition, which in the opinion of the treating physician would make this protocol unreasonably hazardous for the patient
  • Dyspnea at rest or other diseases that require continuous oxygen therapy
  • Patients with poorly controlled diabetes or with evidence of clinically significant diabetic vascular complications
  • Patients with known infection with , virus, or virus
  • Male patients
  • Pregnant, lactating or women of without a negative pregnancy test (serum) within 7 days prior to randomization, irrespective of the method of used
  • Medical or psychological conditions that would not permit the subject to complete the study or sign
  • Participation in another clinical study within the 30 days before registration
  • Legal incapacity or limited legal capacity
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
271 participants (actual)

Study arms

  • Experimental
    Chemotherapy with docetaxel

    dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus docetaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Docetaxel

  • Experimental
    Chemotherapy with paclitaxel

    dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus paclitaxel.Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Paclitaxel

  • Experimental
    Chemotherapy with vinorelbine

    dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus vinorelbine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Vinorelbine

  • Experimental
    Chemotherapy with capecitabine

    dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus capecitabine. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Capecitabine

  • Experimental
    endocrine therapy with exemestane

    dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus exemestane.

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Exemestane · Drug: Ribociclib

  • Experimental
    endocrine therapy with fulvestrant

    dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus fulvestrant.

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Fulvestrant · Drug: Ribociclib

  • Experimental
    endocrine therapy with anastrozole

    dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus anastrozole.

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Anastrozole · Drug: Ribociclib

  • Experimental
    endocrine therapy with letrozole

    dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus letrozole.

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Letrozole · Drug: Ribociclib

  • Experimental
    Chemotherapy with nab-Paclitaxel

    dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus nab-Paclitaxel. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).

    Drug: pertuzumab · Drug: Trastuzumab · Drug: nab-Paclitaxel

  • Experimental
    Chemotherapy with eribulin

    dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus eribulin. Up to three weeks after completion of chemotherapy, patients will be treated with maintenance endocrine therapy plus dual HER2-targeted therapy and Kisqali® (Ribociclib).

    Drug: pertuzumab · Drug: Trastuzumab · Drug: eribulin

  • Experimental
    endocrine therapy with leuprorelin

    dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus leuprorelin.

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Ribociclib · Drug: leuprorelin

  • Experimental
    endocrine therapy with goserelin

    dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (Ribociclib) plus goserelin.

    Drug: pertuzumab · Drug: Trastuzumab · Drug: Ribociclib · Drug: goserelin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    safety of a dual HER2-targeted therapy with Herceptin® (trastuzumab), Perjeta® (pertuzumab) and Kisqali® (riobciclib) plus endocrine therapy as compared to a dual HER2-targeted therapy with Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus chemotherapy (followed by endocrine therapy plus ribociclib in combination with trastuzumab and pertuzumab as maintenance therapy) by the proportion of patients experiencing any adverse event (as defined by the modified adverse event score)

    Time frame: 3 - 9 weeks

Secondary outcomes

  1. quality-adjusted survival

    to assess quality-adjusted survival (as assessed by the Q-TWiST method) and to compare it between the two treatment arms

    Time frame: 3 - 9 weeks

  2. overall response rate (ORR)

    compare efficacy between the two treatment arms as assessed by overall response rate (ORR)

    Time frame: 3 - 9 weeks

  3. incidence of central nervous system (CNS) metastases and their control rate

    assess the incidence of CNS metastases and control rate of preexisting CNS metastases

    Time frame: 3 - 9 weeks

  4. Analysis of Quality of life

    assess additional aspects of quality of life based on the evaluation of the European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) QLQ-C30 and QLQ-BR23 questionnaires

    Time frame: 3 - 9 weeks

  5. presence and number of circulating tumor cell (CTC) at different time points

    determine presence and number of CTC in the peripheral blood at baseline and at different time points after the start of palliative treatment including the time of progression, and to assess the value of CTCs as indicator for therapy success

    Time frame: 6 weeks

  6. Evaluation of all reported events and all grades in both treatment arms (chemotherapy and endocrine therapy)

    All reported events with all grades for evaluation of safety and tolerability of the study treatments and to to evaluate and compare toxicity of chemotherapy arm vs. endocrine treatment arm

    Time frame: 3 - 9 weeks

  7. disease control rate (DCR)

    compare efficacy between the two treatment arms as assessed by disease control rate (DCR)

    Time frame: 3 - 9 weeks

  8. progression-free survival (PFS)

    compare efficacy between the two treatment arms as assessed by progression-free survival (PFS)

    Time frame: 3 - 9 weeks

  9. overall survival (OS)

    compare efficacy between the two treatment arms as assessed by overall survival (OS)

    Time frame: 3 - 9 weeks

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2015 (actual). Primary completion is estimated for Jan 2025, 112 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 112 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2015
First posted
Jan 26, 2015
StartActual
Sep 2015
Primary completionEst.
Jan 31, 2025
CompletionEst.
Jan 31, 2025
Last update
Jun 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02344472
Lead sponsor
Prof. Wolfgang Janni
Responsible party
Prof. Wolfgang Janni (Director Department of Obstetrics and Gynecology, University of Ulm) — Sponsor-investigator
First posted
Jan 26, 2015
Start date
Sep 2015
Primary completion
Jan 31, 2025 (estimated)
Completion
Jan 31, 2025 (estimated)
Last update
Jun 4, 2024

Study contacts

Jens Huober, MD PhD
principal investigator · Studienzentrale Dpt. Gyn/OB University Ulm

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Exemestane · Anastrozole

Start the discussion